Welkin Health Announces Partnership to Implement An Innovative Program to Support Commercialization of the Axonics® Cutting-Edge Sacral Neuromodulation Therapy

Welkin’s software will streamline workflows for care teams and enable personalized, ongoing support for patients receiving therapy for urinary and fecal dysfunction

Welkin Health, a privately-held patient relationship management software company today announced it is partnering with Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a company focused on the design, development, and commercialization of Sacral Neuromodulation (“SNM”) solutions. The companies will launch a program designed to support care teams and patients implanted with the Axonics r-SNM™ System, the first-ever long-lived rechargeable neurostimulator for patients suffering from overactive bladder and fecal incontinence.

Welkin’s patient management software enables Axonics commercial and clinical support teams to capture and utilize relevant data to support patients and physicians.

Chase Hensel, CEO of Welkin Health said, “The program we’re building with Axonics prioritizes the patient experience. This means the Axonics teams will have the pieces in place to easily manage complex data and guide workflows. We believe that having this tool in place will allow many more patients to benefit from SNM therapy and Axonics’ innovative long-lived technology.”

“We selected to work with Welkin given their software has the ability to seamlessly follow our patients during their journey from intake, through implant and post-operative programming and follow up such that patients feel supported,” commented Raymond W. Cohen, CEO of Axonics. “The Welkin system promises to create efficiencies in our operations allowing us to deploy our field personnel where and when they are needed to support cases.”

About Axonics Modulation Technologies, Inc.

Axonics, based in Irvine, CA, is focused on the development and commercialization of a novel implantable SNM system for patients with urinary and bowel dysfunction. The Axonics r-SNM System is the first rechargeable Sacral Neuromodulation system approved for sale in Europe, Canada and Australia, and the first SNM system to gain CE mark for full-body MRI conditional labeling. Premarket Approval (PMA) for the r-SNM System is currently pending with the U.S. FDA. For more information, visit the Company’s website at www.axonicsmodulation.com.

About Welkin Health

Welkin Health is a digital health company that helps healthcare organizations increase revenue and reduce operational costs with improved health outcomes through engagement, education, and support programs for people living with chronic disease. Our workflow and communication software allows care teams to prioritize patient outreach and reach members on any device, including SMS, phone call, and email. Welkin helps teams focus on building and maintaining long-term relationships with custom configurations of the Welkin Patient Relationship Management platform. For more information about Welkin, visit https://welkinhealth.com